Trial · NCT00869401
Adverse events980
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 980
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Blood disorder | Blood and lymphatic system disorders | Dose Level 0 Phase I | 0 | 3 | 0 |
| other | Blood disorder | Blood and lymphatic system disorders | Dose Level 0-A Phase I | 0 | 3 | 0 |
| other | Blood disorder | Blood and lymphatic system disorders | Dose Level 1 Phase1 | 0 | 7 | 0 |
| other | Blood disorder | Blood and lymphatic system disorders | Group 2 (Phase II) Placebo + Radiation + Temozolomide | 1 | 133 | 1 |
| other | Blood disorder | Blood and lymphatic system disorders | Group 1 (Phase II) Dasatinib + Radiation + Temozolomide | 0 | 63 | 0 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Dose Level 0 Phase I | 0 | 3 | 0 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Dose Level 0-A Phase I | 0 | 3 | 0 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Dose Level 1 Phase1 | 0 | 7 | 0 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Group 2 (Phase II) Placebo + Radiation + Temozolomide | 1 | 133 | 1 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Group 1 (Phase II) Dasatinib + Radiation + Temozolomide | 0 | 63 | 0 |
| other | Hemoglobin decreased | Blood and lymphatic system disorders | Dose Level 0 Phase I | 2 | 3 | 12 |
| other | Hemoglobin decreased | Blood and lymphatic system disorders | Dose Level 0-A Phase I | 2 | 3 | 10 |
| other | Hemoglobin decreased | Blood and lymphatic system disorders | Dose Level 1 Phase1 | 6 | 7 | 37 |
| other | Hemoglobin decreased | Blood and lymphatic system disorders | Group 2 (Phase II) Placebo + Radiation + Temozolomide | 107 | 133 | 379 |
| other | Hemoglobin decreased | Blood and lymphatic system disorders | Group 1 (Phase II) Dasatinib + Radiation + Temozolomide | 41 | 63 | 135 |
| other | Cardiac pain | Cardiac disorders | Dose Level 0 Phase I | 0 | 3 | 0 |
| other | Cardiac pain | Cardiac disorders | Dose Level 0-A Phase I | 0 | 3 | 0 |
| other | Cardiac pain | Cardiac disorders | Dose Level 1 Phase1 | 1 | 7 | 1 |
| other | Cardiac pain | Cardiac disorders | Group 2 (Phase II) Placebo + Radiation + Temozolomide | 0 | 133 | 0 |
| other | Cardiac pain | Cardiac disorders | Group 1 (Phase II) Dasatinib + Radiation + Temozolomide | 0 | 63 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00869401/events